Beyond depression: citalopram for obsessive-compulsive disorder

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Obsessive-compulsive disorder (OCD) treatment has advanced significantly with serotonin reuptake inhibitors (SRIs).
• The specific response of OCD to SRIs has facilitated neurobiological research into the disorder.
• Key investigational areas include neuroimaging, neuroimmunology, and pharmacologic challenge studies.

Purpose of the Study:

• To review the established role of serotonin reuptake inhibitors (SRIs) in treating obsessive-compulsive disorder (OCD).
• To compare currently marketed SRIs for OCD based on efficacy, dosing, and side-effect profiles.
• To introduce citalopram as a potentially advantageous selective serotonin reuptake inhibitor (SSRI) for OCD treatment.

Main Methods:

• Review of existing literature on SRI efficacy in OCD treatment.
• Comparison of pharmacological profiles of approved SSRIs for OCD.
• Examination of citalopram's characteristics in depression treatment for potential OCD application.

Main Results:

• Several SRIs, including clomipramine, sertraline, paroxetine, fluoxetine, and fluvoxamine, are approved for OCD treatment.
• Current SRI selection depends on efficacy, dosing, and side-effect variations.
• Citalopram demonstrates a favorable side-effect profile, low withdrawal risk, and minimal drug interactions in depression treatment.

Conclusions:

• Serotonin reuptake inhibitors (SRIs) are a cornerstone in managing obsessive-compulsive disorder (OCD).
• Differences in efficacy, dosing, and side effects guide the choice among available SRIs.
• Citalopram presents a theoretical potential for effective OCD treatment with an advantageous safety and tolerability profile.